Cambridge Raman Imaging (CRI) joined the launch of the Italian Chapter of Nucleate Italy in Milan, participating in the Pitch Competition for Italian biotech startup in front of several VCs and investors.
Nucleate, a non-profit organization dedicated to empowering the next generation of biotech leaders and facilitating the formation of new life science companies, has just launched the Italian Chapter. Nucleate aims to revolutionise the Italian biotech ecosystem by bringing together stakeholders, investors, entrepreneurs, and innovators in the same place. To mark this milestone on the 26th of November, Nucleate organized an event in Milan featuring a pitch competition. CRI was one of the life science startups selected to pitch in front of a group of investors, which manage a total asset of over 10 Billion. According to Matteo Negro, CEO of CRI, “It was a great venue for a fruitful discussion among experts in the biotech sector and to get an overview of some of Italy’s next-generation life science startups.”
Besides CRI, presenting its Raman spectroscopy device that enables a fast and accurate cancer diagnosis, other startups presented their innovations spanning different fields: therapies for autoimmune diseases and cancer (Altheia Science), nanoparticles for drug delivery (NanoMuG), organs-on-chip for drug screening (BiomimX® Srl), an intraocular device for ocular diseases (MgShell) and sequencing data for omics-based reports (enGenome).
We look forward to the next steps Nucleate will take to support the Italian biotech system, and we are pleased to be part of it from the beginning.